Literature DB >> 25028266

ABC transporters as differentiation markers in glioblastoma cells.

Ana R Rama1, Pablo J Alvarez, Roberto Madeddu, Antonia Aranega.   

Abstract

UNLABELLED: Glioblastoma multiforme (GBM) is the most common primary malignant brain tumour, characterized by a high aggressivity, a huge heterogeneity attending a hierarchical model and resistance to therapy. Drug resistance has been correlated with the presence of the ABC efflux transporters which are able to exclude drugs for the cellular cytoplasm. In the nucleus of the GBM, initiating cells (ICs) can self-renew and give rise to cancer stem cells, which differ to the side population cells and the different cellular subtypes that form the mass around them. The ICs do not express or express ATP binding cassette (ABC) at very low levels, but this expression may increase with the differentiation process. We suggest that the differentiation process may be responsible of chemoresistance of the GBM cells. We compared three ABC transporters expression: ABCA1, MRP4 and MRP5, in the ICs obtained from 9 patients with GBM and their respective differentiated GBM cells. We show an overexpression of the three ABC transporters in the differentiated GBM cells in comparison to ICs. IMPLICATIONS OF THE HYPOTHESIS: The blockade of these ABC transporters could help to improve the drug effectivity and thus reduce the tumour growth and prevent the tumour recurrence.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25028266     DOI: 10.1007/s11033-014-3423-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  14 in total

1.  Prognostic significance of MRP5 immunohistochemical expression in glioblastoma.

Authors:  George A Alexiou; Anna Goussia; Spyridon Voulgaris; Andreas D Fotopoulos; George Fotakopoulos; Antigoni Ntoulia; Anastasia Zikou; Perikles Tsekeris; Maria I Argyropoulou; Athanasios P Kyritsis
Journal:  Cancer Chemother Pharmacol       Date:  2012-01-26       Impact factor: 3.333

2.  Blockade of the NFκB pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo.

Authors:  L Nogueira; P Ruiz-Ontañon; A Vazquez-Barquero; M Lafarga; M T Berciano; B Aldaz; L Grande; I Casafont; V Segura; E F Robles; D Suarez; L F Garcia; J A Martinez-Climent; J L Fernandez-Luna
Journal:  Oncogene       Date:  2011-03-21       Impact factor: 9.867

3.  Better results with the new generation bare metal stents.

Authors:  Harald Vik-Mo
Journal:  Scand Cardiovasc J       Date:  2009-04       Impact factor: 1.589

4.  Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.

Authors:  Praveen K Nambaru; Tobias Hübner; Kathleen Köck; Steffen Mews; Markus Grube; Léa Payen; Jérôme Guitton; Matthias Sendler; Gabriele Jedlitschky; Christian Rimmbach; Dieter Rosskopf; Dariusz W Kowalczyk; Heyo K Kroemer; Frank U Weiss; Julia Mayerle; Markus M Lerch; Christoph A Ritter
Journal:  Drug Metab Dispos       Date:  2010-10-07       Impact factor: 3.922

Review 5.  ABCA1: at the nexus of cholesterol, HDL and atherosclerosis.

Authors:  Alan D Attie
Journal:  Trends Biochem Sci       Date:  2007-02-26       Impact factor: 13.807

6.  Bioimpedance analysis and cardiovascular status in pediatric patients on chronic hemodialysis.

Authors:  Fabio Paglialonga; Gianluigi Ardissino; Maria A Galli; Rosalia V Scarfia; Sara Testa; Alberto Edefonti
Journal:  Hemodial Int       Date:  2012-10       Impact factor: 1.812

7.  Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.

Authors:  Elisa Carra; Federica Barbieri; Daniela Marubbi; Alessandra Pattarozzi; Roberto E Favoni; Tullio Florio; Antonio Daga
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

8.  Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures.

Authors:  Sandrine Eimer; Frédéric Dugay; Kelly Airiau; Tony Avril; Véronique Quillien; Marc-Antoine Belaud-Rotureau; Francis Belloc
Journal:  Neuro Oncol       Date:  2012-10-26       Impact factor: 12.300

9.  Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells.

Authors:  Anna Golebiewska; Sébastien Bougnaud; Daniel Stieber; Nicolaas H C Brons; Laurent Vallar; Frank Hertel; Barbara Klink; Evelin Schröck; Rolf Bjerkvig; Simone P Niclou
Journal:  Brain       Date:  2013-03-04       Impact factor: 13.501

10.  Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells.

Authors:  Audun O Vik-Mo; Johan Fernø; Silje Skrede; Vidar M Steen
Journal:  BMC Pharmacol       Date:  2009-08-29
View more
  6 in total

1.  Transcriptomic Profiling of 3D Glioblastoma Tumoroids for the Identification of Mechanisms Involved in Anticancer Drug Resistance.

Authors:  Nipha Chaicharoenaudomrung; Phongsakorn Kunhorm; Wilasinee Promjantuek; Narawadee Rujanapun; Nudjanad Heebkaew; Natchadaporn Soraksa; Parinya Noisa
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

Review 2.  EGFR Amplification and Glioblastoma Stem-Like Cells.

Authors:  Katrin Liffers; Katrin Lamszus; Alexander Schulte
Journal:  Stem Cells Int       Date:  2015-06-02       Impact factor: 5.443

3.  Licochalcone A specifically induces cell death in glioma stem cells via mitochondrial dysfunction.

Authors:  Kenta Kuramoto; Shuhei Suzuki; Hirotsugu Sakaki; Hiroyuki Takeda; Tomomi Sanomachi; Shizuka Seino; Yoshitaka Narita; Takamasa Kayama; Chifumi Kitanaka; Masashi Okada
Journal:  FEBS Open Bio       Date:  2017-05-08       Impact factor: 2.693

Review 4.  Cholesterol Metabolism: A Potential Therapeutic Target in Glioblastoma.

Authors:  Fahim Ahmad; Qian Sun; Deven Patel; Jayne M Stommel
Journal:  Cancers (Basel)       Date:  2019-01-26       Impact factor: 6.639

Review 5.  Culture conditions defining glioblastoma cells behavior: what is the impact for novel discoveries?

Authors:  Pítia Flores Ledur; Giovana Ravizzoni Onzi; Hui Zong; Guido Lenz
Journal:  Oncotarget       Date:  2017-08-11

6.  Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2.

Authors:  Xin Zhang; Xiuting Liu; Wei Zhou; Mengdi Yang; Yang Ding; Qing Wang; Rong Hu
Journal:  Cell Death Dis       Date:  2018-02-07       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.